<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) has a broad role in the regulation of <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism making it a promising target in the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore sought to characterise for the first time the effects of <z:hpo ids='HP_0011010'>chronic</z:hpo> AMPK activation on skeletal muscle carbohydrate metabolism in carriers of the rare gain-of-function mutation of the gene encoding AMPKgamma(3) subunit, PRKAG3 R225W </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Aspects of fuel metabolism were studied in vitro in myocytes isolated from vastus lateralis of PRKAG3 R225W carriers and matched control participants </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo, muscular strength and <z:mp ids='MP_0002899'>fatigue</z:mp> were evaluated by isokinetic dynamometer and surface electromyography, respectively </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> uptake in exercising quadriceps was determined using [(18)F]fluorodeoxyglucose and <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Myotubes from PRKAG3 R225W carriers had threefold higher <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> content (p &lt; 0.01) and oxidative capacity, higher leak-dependent respiration (1.6-fold, p &lt; 0.05), higher basal <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake (twofold, p &lt; 0.01) and higher <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthesis rates (twofold, p &lt; 0.05) than control myotubes </plain></SENT>
<SENT sid="6" pm="."><plain>They also had higher levels of intracellular <z:chebi fb="15" ids="28087">glycogen</z:chebi> (p &lt; 0.01) and a trend for lower intramuscular triacylglycerol stores </plain></SENT>
<SENT sid="7" pm="."><plain>R225W carriers showed remarkable resistance to muscular <z:mp ids='MP_0002899'>fatigue</z:mp> and a trend for increased <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in exercising muscle in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: Through the enhancement of skeletal muscle <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and increased <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> content, the R225W mutation may significantly enhance exercise performance </plain></SENT>
<SENT sid="9" pm="."><plain>These findings are also consistent with the hypothesis that the gamma(3) subunit of AMPK is a promising tissue-specific target for the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, a condition in which <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function are impaired </plain></SENT>
</text></document>